This report provides detailed analysis of worldwide markets for Codeine (CAS 76-57-3) provides extensive market forecasts (2016-2021) by region/country and subsectors.
It covers the key technological and market trends in the Codeine (CAS 76-57-3) market and further lays out an analysis of the factors influencing the supply/demand for Codeine (CAS 76-57-3), and the opportunities/challenges faced by industry participants.
It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Codeine, also known as 3-methylmorphine, is an opiate used to treat pain, as a cough medicine, and for diarrhea. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or aspirin.
Evidence does not support its use for cough suppression. In Europe it is not recommended as a cough medicine in those under twelve years of age. It is taken by mouth. It typically starts working after half an hour with maximum effect at two hours.
Effects last for about four to six hours. Common side effects include vomiting, constipation, itchiness, and lightheadedness. Serious side effects may include a decreased effort to breathe and addiction. It is unclear if its use in pregnancy is safe.
Care should be used during breastfeeding as it may result in opiate toxicity in the baby. Codeine works following being broken down by the liver into morphine. How quickly this occurs depends on a person's genetics.
Codeine was discovered in 1832 by Pierre Jean Robiquet. In 2013 about 361,000 kilograms of codeine were produced while 249,000 kilograms were used. This makes it the most commonly taken opiate.
It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. The wholesale cost is between 0.04 and 0.29 USD per dose as of 2014. In the United States it costs about one dollar a dose. Codeine occurs naturally and makes up about 2% of opium.
GCC's report, Global Codeine (CAS 76-57-3) Industry has been prepared based on the synthesis, analysis, and interpretation of information about the global Codeine (CAS 76-57-3) market collected from specialized sources.
Sample Request:
http://www.radiantinsights.com/research/global-codeine-cas-76-57-3-industry-report-2016/request-sample#tab4
The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players.
The major players in the global Codeine (CAS 76-57-3) market areNoramco, TMO, Alcaliber, Francopia, GSK Tasmania, Tasmanian Alkaloids, Weifa ASA, Macfarlan Smith. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Codeine (CAS 76-57-3) industry has been provided.
It covers the key technological and market trends in the Codeine (CAS 76-57-3) market and further lays out an analysis of the factors influencing the supply/demand for Codeine (CAS 76-57-3), and the opportunities/challenges faced by industry participants.
It also acts as an essential tool to companies active across the value chain and to the new entrants by enabling them to capitalize the opportunities and develop business strategies.
Codeine, also known as 3-methylmorphine, is an opiate used to treat pain, as a cough medicine, and for diarrhea. It is typically used to treat mild to moderate degrees of pain. Greater benefit may occur when combined with paracetamol (acetaminophen) or aspirin.
Evidence does not support its use for cough suppression. In Europe it is not recommended as a cough medicine in those under twelve years of age. It is taken by mouth. It typically starts working after half an hour with maximum effect at two hours.
Effects last for about four to six hours. Common side effects include vomiting, constipation, itchiness, and lightheadedness. Serious side effects may include a decreased effort to breathe and addiction. It is unclear if its use in pregnancy is safe.
Care should be used during breastfeeding as it may result in opiate toxicity in the baby. Codeine works following being broken down by the liver into morphine. How quickly this occurs depends on a person's genetics.
Codeine was discovered in 1832 by Pierre Jean Robiquet. In 2013 about 361,000 kilograms of codeine were produced while 249,000 kilograms were used. This makes it the most commonly taken opiate.
It is on the WHO Model List of Essential Medicines, the most important medications needed in a basic health system. The wholesale cost is between 0.04 and 0.29 USD per dose as of 2014. In the United States it costs about one dollar a dose. Codeine occurs naturally and makes up about 2% of opium.
GCC's report, Global Codeine (CAS 76-57-3) Industry has been prepared based on the synthesis, analysis, and interpretation of information about the global Codeine (CAS 76-57-3) market collected from specialized sources.
Sample Request:
http://www.radiantinsights.com/research/global-codeine-cas-76-57-3-industry-report-2016/request-sample#tab4
The report covers key technological developments in the recent times and profiles leading players in the market and analyzes their key strategies. The competitive landscape section of the report provides a clear insight into the market share analysis of key industry players.
The major players in the global Codeine (CAS 76-57-3) market areNoramco, TMO, Alcaliber, Francopia, GSK Tasmania, Tasmanian Alkaloids, Weifa ASA, Macfarlan Smith. The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, global competitive landscape and supply/demand pattern of Codeine (CAS 76-57-3) industry has been provided.
No comments:
Post a Comment